Operator: Good morning and welcome to Agenus Inc.’s Fourth Quarter and Year-End 2024 Earnings Conference Call. Currently all ...
Baird lowered the firm’s price target on Agenus (AGEN) to $3 from $6 and keeps a Neutral rating on the shares. The firm updated its model ...
Investors are wary about worrisome market signs, after a steep U.S. stocks selloff that has wiped out more than $4 trillion ...
Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all ...
Agenus ( AGEN) shares slipped in morning trade after the company missed fourth quarter revenue estimates. The company reported fourth quarter revenue, including non-cash royalties, of $26.8M, down ...
2seventy bio Inc (TSVT) is expected to report $-0.19 for 4Q. Achieve Life Sciences Inc (ACHV) is expected to report $-0.31 for 4Q. Agenus Inc (AGEN) is expected to report for 4Q. Ascent Solar ...
14d
Zacks Investment Research on MSNAgilent Q1 Earnings Beat Estimates, Stock Falls on Cautious FY25 ViewAgilent Technologies A reported first-quarter fiscal 2025 earnings of $1.31 per share, which beat the Zacks Consensus Estimate by 3.15%. The figure increased 1.6% year over year. Find the latest EPS ...
After Ramadan and the Eid-ul-Fitr holidays, both office hours and trading schedules will return to their normal timings. Under normal circumstances, the stock exchange operates from 10am to 2:20pm ...
Chemring yesterday bolstered its defences against a possible takeover bid with a bumper trading update and a £ ... could further hollow out the sector after a rash of overseas buyouts in recent ...
LEXINGTON, Mass., February 26, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping ...
In trading with the Houston Astros for outfielder Kyle Tucker - one of the best all around players in the sport - the Cubs acquired a superstar the caliber of which it takes to win championships ...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results